Mabion S.A.

Overview
Biosimilars?
Product stageSegments
Seed
?
Diversified Drug Developers, Contract Development and Manufacturing Organizations
?

Mabion S.A. is a Polish biotechnology company focused on developing and manufacturing biosimilar and innovative biological medicines. The company's primary product is MabionCD20, a biosimilar version of rituximab, which is in advanced stages of development for the treatment of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis (RA). Mabion utilizes its own proprietary technology platforms for the development and production of monoclonal antibodies.

In March 2021, Mabion expanded its operations by entering into a manufacturing agreement with Novavax for the production of the Covid-19 vaccine antigen. This collaboration was extended in June 2024, demonstrating the company's growing capabilities in contract manufacturing. Mabion operates a state-of-the-art manufacturing facility in Konstantynów Łódzki, Poland, which received Good Manufacturing Practice (GMP) certification for both active substance and medicinal product manufacturing in July and August 2019, respectively.

The company has been actively pursuing regulatory approvals for MabionCD20. In June 2018, Mabion submitted a marketing authorization application for MabionCD20 to the European Medicines Agency (EMA). However, in March 2020, the company withdrew this application to implement a new regulatory strategy. As of January 2024, Mabion was continuing its efforts to obtain marketing authorization for MabionCD20 in both European and US markets.

In addition to its biosimilar development, Mabion is also engaged in innovative drug development. The company has filed patent applications for its MabionMS project, indicating ongoing research in the field of multiple sclerosis treatment.

Key customers and partnerships

Mabion's primary commercial partnership is with Novavax, Inc. In March 2021, Mabion entered into a framework agreement with Novavax for the contract manufacturing of the SARS-CoV-2 vaccine antigen. This collaboration was strengthened in October 2021 when Mabion signed a commercial manufacturing agreement with Novavax for the period 2022-2025. The partnership was further extended in June 2024, with Mabion concluding an annex to the quality agreement, demonstrating a continued strong relationship between the two companies.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Konstantynów POL
Founded year:
2007
Employees:
51-100
IPO status:
Private
Total funding:
-
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.